Pfizer and BioNTech have announced the effectiveness of their vaccine against the Omicron coronavirus strain when three doses are given.
As shown by the preliminary results of the study, after the third dose, the required level of neutralizing antibodies to the Omicron-variant is reached, with reference to the company’s press release, TASS reports:
“Preliminary data show that the third dose elicits a similar level of neutralizing antibodies to the Omicron variant as seen after two doses against other strains that occurred before it.”
At two doses, the effectiveness of the vaccine against the new strain is much lower:
“The neutralizing potential is reduced by more than 25 times. This indicates that two doses of BNT162b2 do not provide sufficient protection against omicron strain contamination.”
Ugur ahin, head of BioNTech, explains that booster vaccinations can provide sufficient protection against any severity of disease caused by the Omicron variant.
More Stories
Shocking report from Japanese scientists: “Cancer deaths increase sharply after mass Covid vaccination”
Study: Scientists have discovered why children are more susceptible to coronavirus
22 arrests and confiscations took place in Italy and other EU countries in the case of "covid" EU funds (video)